2019 - Member of the National Academy of Medicine (NAM)
Member of the Association of American Physicians
Elizabeth M. Jaffee focuses on Immunology, Immunotherapy, Immune system, Pancreatic cancer and Cancer. In most of her Immunology studies, her work intersects topics such as Survival rate. Her Immunotherapy research is multidisciplinary, relying on both Cancer research, Cyclophosphamide, Chemotherapy and Dendritic cell.
Her studies in Immune system integrate themes in fields like Cytokine and Granulocyte macrophage colony-stimulating factor. The concepts of her Pancreatic cancer study are interwoven with issues in Clinical trial, Tissue microarray, Pancreatic disease and Cancer immunology. She has researched Cancer in several fields, including Radiation therapy and Oncology.
Elizabeth M. Jaffee mostly deals with Cancer research, Immunology, Immune system, Cancer and Immunotherapy. Her studies deal with areas such as Cell, Antibody, Metastasis and Pancreatic cancer as well as Cancer research. Her Pancreatic cancer research incorporates themes from Disease, GVAX and Pancreatic disease, Pancreas.
Her Immune system study frequently involves adjacent topics like Granulocyte macrophage colony-stimulating factor. Her research integrates issues of Cytokine and Pathology in her study of Cancer. Her Immunotherapy study incorporates themes from Melanoma and Oncology.
Cancer research, Internal medicine, Immune system, Oncology and Tumor microenvironment are her primary areas of study. Her study in Cancer research is interdisciplinary in nature, drawing from both Cancer, Metastasis, Cell, T cell and CD8. Her Internal medicine and GVAX, Pancreatic cancer, Chemotherapy, Adenocarcinoma and Disease investigations all form part of her Internal medicine research activities.
Her Immune system research incorporates elements of Myeloid, Carcinoma and Mass cytometry. Her research in Oncology intersects with topics in Clinical endpoint, Clinical trial, Maintenance therapy and Nivolumab, Immunotherapy. Her Immunotherapy research includes themes of Colorectal cancer and Melanoma.
The scientist’s investigation covers issues in Cancer research, Internal medicine, Oncology, Immunotherapy and Pancreatic cancer. The various areas that Elizabeth M. Jaffee examines in her Cancer research study include Cell, Metastasis, Immune system and Cancer immunotherapy. Her biological study spans a wide range of topics, including Mutation and Exome sequencing.
Elizabeth M. Jaffee has included themes like Mesothelin, Cancer, Clinical trial, Survival rate and Combination therapy in her Oncology study. The study incorporates disciplines such as Biomarker, Colorectal cancer, Disease and Pancreatic ductal adenocarcinoma in addition to Immunotherapy. Her Pancreatic cancer research is multidisciplinary, incorporating perspectives in Stroma, GVAX, Pancreas and Effector.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Vaccination with Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-Macrophage Colony-Stimulating Factor Stimulates Potent, Specific, and Long-Lasting Anti-Tumor Immunity
Glenn Dranoff;Elizabeth Jaffee;Audrey Lazenby;Paul Golumbek.
Proceedings of the National Academy of Sciences of the United States of America (1993)
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Siân Jones;Xiaosong Zhang;D. Williams Parsons;D. Williams Parsons;Jimmy Cheng Ho Lin.
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan;Alexander Hopkins;Elizabeth M. Jaffee.
The New England Journal of Medicine (2017)
Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.
Francesco M. Marincola;Elizabeth M. Jaffee;Daniel J. Hicklin;Soldano Ferrone.
Advances in Immunology (2000)
Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
Alex Y. C. Huang;Paul Golumbek;Mojgan Ahmadzadeh;Elizabeth Jaffee.
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T.A. Chan;M. Yarchoan;E. Jaffee;C. Swanton.
Annals of Oncology (2019)
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Siân Jones;Siân Jones;Ralph H. Hruban;Mihoko Kamiyama;Michael Borges.
Mechanisms of immune evasion by tumors.
Charles G. Drake;Elizabeth Jaffee;Drew M. Pardoll.
Advances in Immunology (2006)
Mesothelin Is Overexpressed in the Vast Majority of Ductal Adenocarcinomas of the Pancreas: Identification of a New Pancreatic Cancer Marker by Serial Analysis of Gene Expression (SAGE)
Pedram Argani;Christine Iacobuzio-Donahue;Byungwoo Ryu;Christophe Rosty.
Clinical Cancer Research (2001)
Targeting neoantigens to augment antitumour immunity
Mark Yarchoan;Burles A. Johnson;Eric R. Lutz;Daniel A. Laheru.
Nature Reviews Cancer (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: